

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Paola AMMANNATI
Serial No. : Not yet known
Filed : Simultaneously
For : ENZYMATIC TREATMENT OF RETINITIS
PIGMENTOSA AND RELEVANT
PHARMACEUTICAL COMPOSITION
THEREFOR IN FORM OF A KIT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submits herewith information which they believe may be material to examination of this Application, in respect of which there may be a duty to disclose in accordance with 37 C.F.R. §§ 1.56 and 1.97.

While this Information Disclosure Statement may be material pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that the information referred to therein is "prior art" to Applicants' invention unless designated as such.

In accordance with 37 C.F.R. § 1.97, the filing of this Statement shall not be construed to be an admission that the information attached to this Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56.

By this submission, Applicants also do not represent that a search has been made nor that better art does not exist.

In addition, Applicants reserve the right to contend, as appropriate, that any information asserted against any claim(s) of the captioned Application is not “prior art” according to the facts and the law.

Applicants further reserve the right to present appropriate arguments and/or evidence to establish patentability over such information, should any citation listed below be applied against any claim(s) of the captioned Application.

Applicants respectfully request that the Examiner, after considering the information set forth below, independently determine those citations which the Examiner would consider to be the most pertinent.

A copy of the following citation is submitted along with PTO Form-1449.

Sahel et al., FR 2 784 898, dated April 28, 2000: is directed to “utilisation du GDNF pour le traitement de la degenerescence retinienne”.

Picaud et al., FR 2 784 030, dated April 7, 2000: is directed to “utilisation de bloqueurs des canaux calciques et/ou CGMP-dependents pour le traitement de pathologies de la retine”.


Ling-Hua Zeng et al., “Genetic Study of Retinitis Pigmentosa in China”, *Ophthalmologica*, Vol. 194, No. 1, 1987, pp. 34-39, XP009010425.

E.M. Gloria et al., “The Pathogenesis of Retinitis Pigmentosa. A Pilot Study on the Clinical Fluoroangiographic and Enzymatic Effect of Bendazac Lysine”, *Bollettino di Oculistica*, Vol. 69, No. 2, 1990, pp. 309-318, XP002240485.

It is requested that the above be made of record in this Application.

Respectfully submitted,

Dated: March 31, 2005



Grant E. Pollack, Esq.
Registration No. 34,097
POLLACK, P.C.
The Chrysler Building
132 East 43rd Street, Suite 760
New York, New York 10017
(646) 265-1468

Attorney for Applicants

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Label No. EV 592479779 US, in an envelope with sufficient postage addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

On March 31, 2005

Name Grant E. Pollack



Signature

March 31, 2005

Date of Signature

